Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Could vaccines ease the opioid overdose crisis?

By Brian Buntz | December 30, 2020

Fentanyl

A left-to-right comparison of lethal heroin, carfentanil and fentanyl doses, according to the U.S. DEA.

Vaccines are playing a central role in the fight against COVID-19. They also may hold promise to help relieve the opioid overdose crisis that has worsened along with the pandemic.

That’s the argument that two psychiatrists make in a recent JAMA article, “The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic.” Antifentanyl vaccines have shown promise in trials, but none are commercially available. 

At the outset of the COVID-19 pandemic, it seemed likely that decreased access to illegal drugs, increased telemedicine access and loosened federal methadone restrictions would reduce opioid overdoses, argue the psychiatrist authors Dr. Thomas Kosten and Dr. Ismene Petrakis in the article. But instead, overdoses have climbed. In May 2020, there were 42% more overdoses than in the same month a year prior. 

Fentanyl, the synthetic opioid analgesic that the Drug Enforcement Administration says is 80 to 100 times more potent than morphine, is driving the bulk of overdose deaths. But the most common treatments for opiate use disorder, buprenorphine and methadone, do not inhibit fentanyl distribution to the brain. 

Vaccines to combat the effects of fentanyl have the potential to improve the situation. Animal experiments involving antifentanyl vaccines have shown promising results, but there is little support for such vaccines.  

COVID-19 vaccine development initiatives have received more than 1,000 times more support than antifentanyl vaccine projects, the JAMA article concluded. Yet, the templates for such vaccines were developed 50 years ago. 

One central challenge is the stigma against opioid use disorder, which has arguably worsened after the COVID-19 outbreak as many clinicians have deprioritized addiction treatment during the pandemic. 

Current treatments for opioid use disorder have not been insufficient to contain the worsening opioid overdose crisis. “We need to return our attention to this hidden epidemic that was very much in the public eye before the COVID-19 pandemic struck and that COVID-19 appears to have worsened,” Kosten and Petrakis conclude.  

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: clinical trials, coronavirus, covid-19, COVID-19 vaccine, fentanyl, opioid abuse, opioid overdose crisis, opioid use disorder
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Sai Life Sciences to double process R&D capacity with new Hyderabad facility
How stereo-correct data can de-risk AI-driven drug discovery
Pfizer stock jumps 14% as TrumpRx drug pricing deal eases tariff fears
See it in 1 second, act in 60: Eschbach’s take on how visual factories enable measurable decisions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE